Covered recipient · General Payments record
CLAIRE G REYNOLDS
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Adult Health
General Payments · PY2022–2024
$1,658.29
- Reported across 52 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $523.07 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $145.02 | 2 |
| Corcept Therapeutics | $112.53 | 1 |
| Radius Health, Inc. | $73.38 | 3 |
| Amgen Inc. | $67.66 | 4 |
| Lilly USA, LLC | $40.51 | 2 |
| ABBVIE INC. | $35.05 | 2 |
| RECORDATI_RARE_DISEASES_INC. | $24.52 | 1 |
| IBSA Pharma Inc. | $24.40 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $18.64 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108078398 | CMS |
| ABBVIE INC. | $16.41 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108078400 | CMS |
| Amgen Inc. | $13.96 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115444988 | CMS |
| Amgen Inc. | $18.56 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115444992 | CMS |
| Amgen Inc. | $14.71 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115444985 | CMS |
| Amgen Inc. | $20.43 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115444980 | CMS |
| Corcept Therapeutics | $112.53 | 06/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117760170 | CMS |
| IBSA Pharma Inc. | $24.40 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142981455 | CMS |
| Lilly USA, LLC | $21.76 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135598063 | CMS |
| Lilly USA, LLC | $18.75 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135558012 | CMS |
| Novo Nordisk Inc | $125.00 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100525359 | CMS |
| Novo Nordisk Inc | $20.02 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100585046 | CMS |
| Radius Health, Inc. | $17.55 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1090011880 | CMS |
| Radius Health, Inc. | $24.28 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1090011871 | CMS |
| Radius Health, Inc. | $31.55 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1090011875 | CMS |
| RECORDATI_RARE_DISEASES_INC. | $24.52 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139170523 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.